加载中
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
NASDAQHealthcareBiotechnology
最新数据
US$1.16
−US$0.02 · -1.69%
前收盘价
US$1.16
−US$0.02 · -1.69%
盘后
US$1.20
+US$0.04 · +3.45%
10月12日 19:58 ET
盘中时间采用ET。市场数据可能有所延迟。
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
日内区间
当前US$1.16
52周区间
当前US$1.16
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
65
低估
情绪
56
多空交织
风险
81
极高风险
动量
17
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
日内区间
当前US$1.16
52周区间
当前US$1.16
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 131.1万 USD | 65.8万 USD | — | — | — |
| 销货成本 | 396.3万 USD | 123.8万 USD | — | — | 74.76万 USD |
| 毛利 | −265.2万 USD | −58万 USD | — | — | −74.76万 USD |
| 研究与开发 | 236.9万 USD | 553.2万 USD | 521万 USD | 576.5万 USD | 262.37万 USD |
| 销售、一般及管理费用 | 252.1万 USD | 252.6万 USD | 450.5万 USD | 529.6万 USD | 742.36万 USD |
| 营业费用 | 489万 USD | 805.8万 USD | 970.6万 USD | 1106.1万 USD | 1004.73万 USD |
| 利息收入 | 2万 USD | 10.05万 USD | 392.4万 USD | 305.1万 USD | 928.76 USD |
| 利息支出 | 35.9万 USD | 143.88万 USD | 380.1万 USD | — | 336.36万 USD |
| 折旧和摊销 | 142.1万 USD | 164.9万 USD | 51.4万 USD | 56.2万 USD | 47.1万 USD |
| 营业利润 | −754.2万 USD | −863.8万 USD | −970.6万 USD | −1106.1万 USD | −1079.49万 USD |
| 净利润 | −830.7万 USD | 479.6万 USD | −650万 USD | −579.6万 USD | −1237.66万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年8月21日 | 1:10 | — | — |
股票拆分 | 2024年5月21日 | 1:10 | — | — |
股票拆分 | 2022年11月25日 | 1:10 | — | — |
已生效 2026年8月21日
1:10
已生效 2024年5月21日
1:10
已生效 2022年11月25日
1:10
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
